Top Page
ConvaTec
(LSE:CTEC)
ConvaTec (CTEC) vs. iShares MSCI United Kingdom ETF (EWC)
ConvaTec Business Overview & Revenue Model
ConvaTec Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.36B | 2.29B | 2.14B | 2.07B | 2.04B | 1.89B |
| Gross Profit | 1.32B | 1.28B | 1.20B | 1.12B | 1.12B | 1.02B |
| EBITDA | 570.70M | 540.20M | 455.50M | 419.10M | 405.40M | 390.70M |
| Net Income | 216.70M | 190.50M | 130.30M | 62.90M | 117.60M | 112.50M |
Balance Sheet | ||||||
| Total Assets | 3.77B | 3.52B | 3.71B | 3.59B | 3.67B | 3.77B |
| Cash, Cash Equivalents and Short-Term Investments | 95.70M | 64.70M | 98.30M | 145.80M | 463.40M | 565.40M |
| Total Debt | 1.34B | 1.20B | 1.31B | 1.30B | 1.44B | 1.55B |
| Total Liabilities | 1.96B | 1.83B | 2.02B | 1.98B | 1.98B | 2.10B |
| Stockholders Equity | 1.81B | 1.69B | 1.69B | 1.61B | 1.69B | 1.67B |
Cash Flow | ||||||
| Free Cash Flow | 349.60M | 274.10M | 238.20M | 137.50M | 211.80M | 313.30M |
| Operating Cash Flow | 477.70M | 396.20M | 367.40M | 281.70M | 305.90M | 399.50M |
| Investing Cash Flow | -180.90M | -160.80M | -285.70M | -348.30M | -206.50M | -56.30M |
| Financing Cash Flow | -297.60M | -263.80M | -124.00M | -237.10M | -199.90M | -162.10M |
ConvaTec Technical Analysis
ConvaTec Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | £12.02B | 32.64 | 9.30% | 2.03% | 2.51% | 56.56% | |
75 Outperform | £3.89B | 13.61 | 15.66% | 3.61% | 3.73% | 27.13% | |
74 Outperform | £4.85B | 29.91 | 12.73% | 2.06% | 4.18% | 37.65% | |
64 Neutral | £467.12M | 50.82 | 3.66% | 1.24% | 68.03% | -18.27% | |
64 Neutral | £813.66M | 53.44 | 6.00% | 1.27% | 5.74% | 63.23% | |
62 Neutral | £927.47M | 50.11 | 2.51% | 1.00% | 6.95% | -34.38% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
ConvaTec Corporate Events
ConvaTec Group PLC has executed a share buyback transaction, purchasing over 2.24 million ordinary shares as part of its previously announced $300 million share buyback program. The shares were acquired at prices ranging from 241.20 to 243.80 pence and will be held in treasury. This move is part of ConvaTec’s strategy to optimize its capital structure and return value to shareholders, reflecting confidence in its financial position and future prospects.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £270.00 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
ConvaTec Group PLC has executed a share buyback, purchasing 2,372,762 ordinary shares as part of its $300 million buyback program announced earlier in August 2025. The shares were acquired at prices ranging from 242.00 to 246.00 pence and will be held in treasury, impacting the company’s share capital structure and potentially enhancing shareholder value.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £2.82 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
ConvaTec Group PLC has executed a share buyback, purchasing 1,560,372 ordinary shares as part of its $300 million share buyback program announced in August 2025. The shares, bought at an average price of 247.41 pence, will be held in treasury, increasing the company’s treasury shares to 54,552,058. This move is likely aimed at enhancing shareholder value and optimizing the company’s capital structure.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £2.82 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
ConvaTec Group plc is spearheading a pivotal study titled ‘A Multi-Centre, Observer-Blinded, Randomized Controlled Trial of EDX110 for the Treatment of Diabetic Foot Ulcers.’ The study aims to evaluate whether the EDX110 dressing system, when added to the standard care regimen, enhances the healing of diabetic foot ulcers compared to standard care alone. This research holds significant potential for improving patient outcomes in wound healing.
ConvaTec Group plc is conducting a clinical study titled ‘An Observer-Blinded Multicenter Randomized Controlled Trial Evaluating Porcine Placental Extracellular Matrix as an Adjunct to Standard of Care Versus Standard of Care Alone in Hard-to-Heal Venous Leg Ulcers.’ The study aims to assess the efficacy of porcine placental extracellular matrix (PPECM) combined with standard care in treating non-healing venous leg ulcers, which are challenging to manage and significantly impact patient quality of life.
ConvaTec Group plc is currently conducting a clinical study titled ‘Evaluating the Efficacy of Porcine Placental Extracellular Matrix Augmented Wound Care Against Standard Wound Care for the Management of Diabetic Foot Ulcers.’ The study aims to assess the effectiveness of adding Porcine Placental Extracellular Matrix (PPECM) to standard care in treating diabetic foot ulcers, a significant health concern due to its challenging healing process.
ConvaTec Group plc is conducting a study titled ‘SCOPE – Single-Point Classification Observational Peristomal Evaluation’ to assess the interrater reliability of SACS 2.0 for evaluating peristomal skin health in ostomates. This observational study aims to create a comprehensive dataset of ostomy images, comparing digital evaluations with traditional in-person assessments, which could significantly enhance clinical practices and patient outcomes.
Convatec has announced the passing of its CEO, Karim Bitar, who had been on medical leave since August 2025. The company has expressed deep sorrow over the loss and extended condolences to his family. Interim leadership arrangements are currently in place, and further announcements will be made in due course. This development is significant for Convatec as it navigates leadership transitions while maintaining its market position in the medical solutions industry.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £2.82 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
ConvaTec Group PLC has executed a share buyback transaction, purchasing 285,122 ordinary shares as part of its $300 million share buyback program announced in August 2025. The shares were bought at prices ranging from 247.00 to 249.00 pence and will be held in treasury. This move is part of ConvaTec’s strategy to optimize its capital structure and return value to shareholders, potentially enhancing its market position and investor confidence.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £2.82 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
ConvaTec Group PLC has announced the repurchase of 952,813 ordinary shares as part of its $300 million share buyback program. This strategic move is aimed at optimizing the company’s capital structure and potentially enhancing shareholder value by reducing the number of shares in circulation, thereby increasing earnings per share.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £2.82 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
ConvaTec Group PLC has announced the repurchase of 735,364 ordinary shares as part of its ongoing $300 million share buyback program initiated in August 2025. This transaction reflects ConvaTec’s commitment to enhancing shareholder value and optimizing its capital structure, with the purchased shares being held in treasury. The company’s total voting rights now stand at 1,998,035,808 ordinary shares, excluding treasury shares, which may impact shareholder notifications under regulatory guidelines.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £2.82 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
ConvaTec Group PLC has executed a share buyback program, purchasing over 1.1 million of its ordinary shares through UBS AG London Branch. This move is part of a previously announced $300 million buyback initiative, aimed at optimizing the company’s capital structure and enhancing shareholder value. The purchased shares will be held in treasury, and the company now holds over 51 million shares in treasury, with nearly 2 billion shares in issue, impacting shareholder voting rights and potentially influencing market perceptions of the company’s financial health.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £2.82 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
ConvaTec Group PLC has executed a share buyback, acquiring over one million of its ordinary shares through UBS AG London Branch as part of a $300 million program announced earlier. This move is expected to enhance shareholder value and optimize the company’s capital structure, reflecting confidence in its financial stability and future growth prospects.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £2.82 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
ConvaTec Group PLC announced the purchase of 439,212 ordinary shares as part of its $300 million share buyback program initiated in August 2025. This strategic move, executed through UBS AG London Branch, is designed to enhance shareholder value and optimize the company’s capital structure, reflecting ConvaTec’s commitment to returning capital to shareholders.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £2.82 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
ConvaTec Group PLC has announced a purchase of 420,064 ordinary shares as part of its ongoing $300 million share buyback program. This move is expected to enhance shareholder value by reducing the number of shares in circulation, thereby potentially increasing earnings per share and reflecting the company’s confidence in its financial position.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £2.82 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
ConvaTec Group PLC announced the purchase of 980,727 ordinary shares as part of its $300 million share buyback program initiated in August 2025. This strategic move is intended to enhance shareholder value and optimize the company’s capital structure, reflecting confidence in its financial health and future prospects.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £2.82 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
ConvaTec Group PLC has executed a share buyback transaction, purchasing 948,052 ordinary shares as part of its $300 million share buyback program announced in August 2025. The shares were bought at prices ranging between 238.80 and 241.80 pence and will be held in treasury. This move aims to optimize the company’s capital structure and potentially enhance shareholder value by reducing the number of shares in circulation, thereby increasing earnings per share.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £2.82 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
ConvaTec Group PLC has executed a share buyback program, purchasing 1,763,576 ordinary shares at prices ranging from 238.00 to 239.80 pence per share, as part of its $300 million buyback initiative announced in August 2025. This strategic move, facilitated through UBS AG London Branch, underscores ConvaTec’s commitment to enhancing shareholder value and optimizing its capital structure, potentially impacting its market positioning and shareholder engagement.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £3.27 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
ConvaTec Group PLC has executed a share buyback transaction, acquiring 2,197,889 ordinary shares as part of a previously announced $300 million buyback program. This move is expected to optimize the company’s capital structure and potentially enhance shareholder value by reducing the number of shares in circulation, thereby increasing earnings per share and providing a signal of confidence in the company’s financial health.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £3.27 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
ConvaTec Group PLC has executed a share buyback as part of its $300 million program, purchasing 633,625 ordinary shares through UBS AG London Branch. The shares, bought at an average price of 241.51 pence, will be held in treasury, affecting the company’s total voting rights and potentially impacting shareholder interests.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £3.27 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
ConvaTec Group PLC announced the purchase of 1,115,198 ordinary shares as part of its $300 million share buyback program. This transaction, executed through UBS AG London Branch, reflects ConvaTec’s strategic initiative to enhance shareholder value by reducing the number of shares in circulation, thereby potentially increasing earnings per share and strengthening its market position.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £3.27 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
ConvaTec Group PLC has announced the purchase of 1,648,655 ordinary shares as part of its ongoing share buyback program, which aims to repurchase shares worth up to $300 million. This move is part of the company’s strategy to manage its capital structure and return value to shareholders, potentially enhancing its market position and shareholder confidence.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £3.27 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
ConvaTec Group PLC has announced the repurchase of 527,553 of its ordinary shares as part of a previously declared $300 million share buyback program. The shares, purchased through UBS AG London Branch, will be held in treasury, impacting the company’s total voting rights and potentially enhancing shareholder value by reducing the number of shares in circulation.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £258.00 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
Convatec Group Plc announced that Non-Executive Director Sharon O’Keefe has transferred 3,200 ordinary shares as a charitable donation to The Chicago Community Trust. This transaction reflects Convatec’s commitment to social responsibility and may enhance its reputation within the industry, potentially impacting stakeholder perceptions positively.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £258.00 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
ConvaTec Group PLC has announced the purchase of 580,718 ordinary shares as part of its ongoing share buyback program, which aims to repurchase up to $300 million worth of shares. This transaction reflects the company’s strategy to enhance shareholder value and optimize its capital structure, potentially impacting its stock market performance and stakeholder interests.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £258.00 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
ConvaTec Group PLC has announced the purchase of 950,470 of its own ordinary shares as part of a share buyback program valued at up to $300 million, initiated on August 20, 2025. The shares, purchased at prices ranging from 232.80 to 236.20 pence, will be held in treasury, impacting the company’s total voting rights and potentially enhancing shareholder value. This move reflects ConvaTec’s strategic focus on optimizing its capital structure and returning value to shareholders, which could strengthen its market position and stakeholder confidence.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £258.00 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
Convatec Group Plc has announced the pricing of a $500 million offering of 5.300% senior notes due in 2035, issued by its subsidiary 180 Medical, Inc. The proceeds from this issuance will be used to refinance existing debt, including prepaying the company’s outstanding term loan facility and a portion of its revolving credit facility, as well as for general corporate purposes. This financial maneuver is expected to strengthen Convatec’s financial position and operational flexibility, potentially impacting its market standing and providing reassurance to stakeholders regarding its debt management strategy.
The most recent analyst rating on (GB:CTEC) stock is a Hold with a £2.50 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
Convatec Group Plc has announced its total voting rights as of September 30, 2025, in compliance with the UK Financial Conduct Authority’s Disclosure and Transparency Rules. The company’s issued share capital consists of 2,049,789,559 ordinary shares, with 34,295,510 shares held in treasury, resulting in 2,015,494,049 voting rights. This information is crucial for shareholders to determine their interest in the company. Additionally, Convatec is in the process of settling 2,077,998 shares purchased under a share buyback program, which will also be held in treasury.
The most recent analyst rating on (GB:CTEC) stock is a Hold with a £2.50 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
ConvaTec Group PLC announced the purchase of over one million of its own shares as part of a $300 million share buyback program. This strategic move is intended to enhance shareholder value and optimize the company’s capital structure, indicating a strong financial position and confidence in future growth prospects.
The most recent analyst rating on (GB:CTEC) stock is a Hold with a £2.50 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
ConvaTec Group PLC has executed a share buyback program, purchasing over a million of its ordinary shares through UBS AG London Branch. This move is part of a previously announced $300 million buyback initiative aimed at enhancing shareholder value. The shares acquired will be held in treasury, and the total voting rights for the company now stand at over 2 billion shares. This strategic financial maneuver underscores ConvaTec’s commitment to optimizing its capital structure and potentially boosting its stock market performance, which could positively impact its stakeholders.
The most recent analyst rating on (GB:CTEC) stock is a Hold with a £2.50 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
ConvaTec Group PLC has announced the purchase of 1,439,340 ordinary shares as part of its $300 million share buyback program, initially announced in August 2025. The shares were acquired at prices ranging from 223.00 to 227.20 pence, with an average price of 225.69 pence per share, and will be held in treasury. This move is part of ConvaTec’s strategy to optimize its capital structure and enhance shareholder value, reflecting confidence in its financial health and future prospects.
The most recent analyst rating on (GB:CTEC) stock is a Hold with a £253.00 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
ConvaTec Group PLC has executed a share buyback transaction, purchasing 1,809,168 ordinary shares as part of its $300 million buyback program announced in August 2025. The shares were acquired at prices ranging from 233.80 to 238.20 pence and will be held in treasury, impacting the company’s total voting rights and potentially influencing shareholder interests.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £266.00 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
ConvaTec Group PLC has announced the purchase of 329,131 ordinary shares as part of a $300 million share buyback program initiated in August 2025. This move is part of the company’s strategy to enhance shareholder value and optimize its capital structure, reflecting confidence in its financial health and future growth prospects.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £3.25 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
ConvaTec Group PLC has executed a share buyback program, purchasing 1,491,986 ordinary shares at prices ranging from 231.00 to 232.60 pence per share. This buyback is part of a larger $300 million program announced in August 2025, and the acquired shares will be held in treasury. This move is likely to impact the company’s share value and provide a strategic advantage in managing its capital structure, potentially benefiting shareholders by increasing the value of remaining shares.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £3.25 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
ConvaTec Group PLC has executed a share buyback program, purchasing over 2 million of its ordinary shares through UBS AG London Branch. This buyback is part of a $300 million program announced in August 2025, aimed at optimizing the company’s capital structure and potentially enhancing shareholder value. The purchased shares will be held in treasury, and the current total voting rights stand at over 2 billion shares, excluding treasury shares.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £260.00 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
ConvaTec Group PLC announced the purchase of 688,220 ordinary shares as part of its $300 million share buyback program. This move, executed through UBS AG London Branch, reflects the company’s strategy to optimize its capital structure and potentially enhance shareholder value by reducing the number of shares in circulation, which could positively impact earnings per share.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £260.00 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
ConvaTec Group PLC has executed a share buyback transaction, purchasing 1,380,335 ordinary shares at a volume-weighted average price of 231.74 pence per share. This move is part of a larger $300 million share buyback program announced in August 2025, which aims to optimize the company’s capital structure and potentially enhance shareholder value. The purchased shares will be held in treasury, adjusting the total voting rights to 2,027,613,359 shares, excluding treasury shares.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £260.00 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
ConvaTec Group PLC has announced the purchase of 1,501,379 ordinary shares as part of its $300 million share buyback program. This transaction, executed through UBS AG London Branch, reflects the company’s strategic initiative to manage its capital structure and potentially enhance shareholder value. The shares will be held in treasury, and the company now holds a total of 20,795,865 shares in treasury, with 2,028,993,694 shares in issue. This move could impact the company’s market positioning by signaling confidence in its financial health and commitment to returning value to shareholders.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £260.00 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
ConvaTec Group PLC has executed a share buyback program, purchasing 1,380,495 ordinary shares at prices ranging from 235.00 to 237.20 pence per share, with an average price of 236.03 pence. This move is part of a larger $300 million buyback initiative announced in August 2025, aimed at optimizing the company’s capital structure and potentially enhancing shareholder value by reducing the number of shares in circulation.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £260.00 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
ConvaTec Group PLC has executed a share buyback program, purchasing 1,575,563 ordinary shares at prices ranging from 235.80 to 238.00 pence per share, as part of a previously announced $300 million buyback initiative. This move is intended to enhance shareholder value by reducing the number of shares in circulation, potentially increasing the value of remaining shares and demonstrating confidence in the company’s financial health.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £260.00 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
Convatec Group Plc announced the grant of share options under its 2017 Save as You Earn scheme to interim executives Jonny Mason and Fiona Ryder. These options, covering a total of 18,686 ordinary shares, are exercisable from September 2028, reflecting the company’s commitment to aligning managerial interests with long-term shareholder value.
The most recent analyst rating on (GB:CTEC) stock is a Hold with a £263.00 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
ConvaTec Group PLC has announced the purchase of 1,354,470 of its ordinary shares as part of a share buyback program valued at up to $300 million, initially announced in August 2025. This move is part of the company’s strategy to manage its capital structure effectively and could potentially enhance shareholder value by reducing the number of shares in circulation, thereby increasing earnings per share.
The most recent analyst rating on (GB:CTEC) stock is a Hold with a £263.00 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
ConvaTec Group PLC has announced the purchase of 1,221,168 ordinary shares as part of its $300 million share buyback program. This strategic move is aimed at optimizing the company’s capital structure and enhancing shareholder value, reflecting confidence in its financial health and future prospects.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £315.00 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
ConvaTec Group PLC has announced the purchase of 1,194,433 ordinary shares as part of its $300 million share buyback program. The shares were acquired through UBS AG London Branch and will be held in treasury. This move is part of ConvaTec’s strategy to optimize its capital structure and return value to shareholders, potentially enhancing the company’s market position and financial flexibility.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £315.00 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
Convatec has announced the exercise and grant of share options under its 2017 Save as You Earn scheme, involving key executives Jonny Mason and Karim Bitar. Jonny Mason, Interim CEO, exercised options for 10,346 shares, while CEO Karim Bitar was granted options for 10,253 shares. These transactions highlight Convatec’s commitment to aligning managerial interests with company performance, potentially impacting stakeholder confidence and market positioning.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £315.00 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
ConvaTec Group PLC has executed a share buyback program, purchasing over 1.19 million ordinary shares at an average price of 239.24 pence per share. This move is part of a larger $300 million buyback initiative announced in August 2025, aimed at optimizing the company’s capital structure and enhancing shareholder value.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £315.00 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
ConvaTec Group PLC has executed a share buyback, purchasing 1,075,326 ordinary shares as part of its $300 million share buyback program announced in August 2025. The shares, bought at a volume-weighted average price of 239.32 pence, will be held in treasury, impacting the company’s total voting rights and potentially influencing shareholder interests.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £315.00 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
Convatec announced that Fiona Ryder, the Interim Chief Financial Officer, exercised options over 10,346 shares under the company’s 2017 Save As You Earn scheme. This transaction reflects internal managerial movements and the company’s ongoing commitment to its employee share option schemes, potentially impacting stakeholder perceptions of Convatec’s financial strategies and executive engagement.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £315.00 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
ConvaTec Group PLC announced the purchase of 1,295,977 ordinary shares as part of its $300 million share buyback program. This strategic move, executed through UBS AG London Branch, is aimed at optimizing the company’s capital structure and enhancing shareholder value. The purchased shares will be held in treasury, and the company now holds a total of 10,295,900 shares in treasury, with 2,039,493,659 shares in issue. This buyback is expected to positively impact the company’s market positioning and shareholder returns.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £315.00 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
ConvaTec Group PLC has announced the purchase of 1,864,441 of its ordinary shares as part of a $300 million share buyback program. This move is part of a strategic initiative to manage the company’s capital structure and potentially enhance shareholder value. The purchased shares will be held in treasury, and following this transaction, the company now holds a total of 8,999,923 ordinary shares in treasury. This buyback could impact the company’s market positioning by potentially increasing earnings per share and providing a signal of confidence in the company’s future prospects.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £315.00 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
ConvaTec Group PLC has executed a share buyback program, purchasing 996,254 ordinary shares at a volume-weighted average price of 238.53 pence per share. This move is part of a larger $300 million buyback initiative announced earlier, aimed at optimizing the company’s capital structure and enhancing shareholder value. The acquired shares will be held in treasury, impacting the total voting rights and share calculations for stakeholders.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £315.00 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
Convatec Group Plc announced its total voting rights, revealing that the company’s issued share capital consists of 2,049,789,559 ordinary shares, with 1,242,173 held in treasury. This results in 2,048,547,386 total voting rights, which shareholders can use to determine their interests under the FCA’s rules. Additionally, 4,897,055 shares are in the settlement process following a recent buyback program. This update could impact shareholder decisions and reflects Convatec’s ongoing financial strategies.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £315.00 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
ConvaTec Group PLC announced the purchase of over 1 million of its own shares as part of a $300 million share buyback program. This move is part of the company’s strategy to enhance shareholder value and optimize its capital structure, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £315.00 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
Convatec Group PLC announced that its Interim Chief Executive Officer, Jonny Mason, and Interim Chief Financial Officer, Fiona Ryder, have both purchased significant shares in the company. Mason acquired 50,000 shares at an average price of 234.81 pence, while Ryder purchased 21,263 shares at 233.96 pence. These transactions, conducted on the London Stock Exchange, reflect a potential vote of confidence in the company’s future prospects by its top executives.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £315.00 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
ConvaTec Group PLC has announced the purchase of 1,137,931 ordinary shares as part of its $300 million share buyback program, initiated on August 20, 2025. The shares, acquired through UBS AG London Branch, will be held in treasury, impacting the company’s total voting rights and potentially influencing shareholder interests under the Financial Conduct Authority’s regulations.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £315.00 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
ConvaTec Group PLC announced the purchase of 1,247,374 ordinary shares as part of its $300 million share buyback program. This strategic move, executed through UBS AG London Branch, aims to enhance shareholder value by reducing the number of shares in circulation, thereby potentially increasing earnings per share and improving market confidence.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £315.00 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
ConvaTec Group PLC has announced the purchase of 1,472,554 ordinary shares as part of its $300 million share buyback program, initiated on August 20, 2025. The shares, bought at a volume-weighted average price of 236.30 pence, will be held in treasury, reflecting the company’s strategy to enhance shareholder value and optimize its capital structure.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £315.00 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
ConvaTec Group PLC has executed a share buyback, purchasing 1,235,062 ordinary shares as part of its $300 million buyback program announced earlier in August 2025. This move is part of the company’s strategy to manage its capital structure and return value to shareholders, potentially enhancing its market position and signaling confidence in its financial health.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £315.00 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
ConvaTec Group PLC has initiated a share buyback program, purchasing 7,111 ordinary shares at a price of 238.40 pence each, as part of a larger $300 million initiative announced on August 20, 2025. This move is expected to strengthen the company’s financial position by reducing the number of shares in circulation, potentially increasing shareholder value and demonstrating confidence in the company’s future performance.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £303.00 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
Convatec Group Plc has announced a share buyback program to return up to $300 million to shareholders, reflecting its disciplined capital allocation strategy. The program, conducted by UBS AG London Branch, aims to reduce Convatec’s share capital and may impact shareholder value by potentially increasing earnings per share.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £300.00 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
Convatec announced that its CEO, Karim Bitar, sold a minority portion of his shares in the company for personal reasons unrelated to the business. Despite this sale, Bitar retains a significant stake in Convatec and expressed confidence in the company’s strong leadership and growth prospects. This transaction, disclosed under the Market Abuse Regulation, is not expected to impact the company’s operations or strategic direction.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £305.00 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
Convatec announced that its Chief Executive Officer, Karim Bitar, will be taking a medical leave of absence. During his absence, Jonny Mason, the current Chief Financial Officer, will serve as the Interim CEO, while Fiona Ryder, the Group Financial Controller, will step in as the Interim CFO. This leadership change is significant for Convatec as it navigates this transition period, potentially impacting its operations and strategic direction.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £305.00 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.